Key Highlights
- Curie.Bio secures $380M for latest fund, nearing $1B total.
- Focus on Series A rounds for clinical proof-of-concept studies.
- Unique VC model supports biotech founders with top-tier R&D services.
- Portfolio includes 20 early-stage therapeutics companies.
- Success story: Forward Therapeutics raised $50M Series A in 18 months.
Source: Business Wire
Notable Quotes
- No quotes were given.
SoHC's Take
Curie.Bio’s recent $380 million fund closure marks a significant milestone, pushing their total funds raised to nearly $1 billion. This substantial capital injection is set to accelerate the growth of early-stage therapeutics companies by focusing on Series A rounds aimed at achieving clinical proof-of-concept. Curie.Bio’s innovative model offers biotech founders unparalleled access to industry-leading drug hunters, operators, and R&D services, effectively lowering the barriers to impactful drug development. Their strategy is clear: by providing comprehensive support from seed stage through clinical trials, Curie.Bio enhances the likelihood of success for new therapies, ensuring founders retain significant control and benefit from their innovations. This model has already proven effective with Forward Therapeutics, demonstrating the potential for rapid development and substantial equity retention. Curie.Bio’s approach is set to redefine the biotech VC landscape, making it a crucial player in the next decade of therapeutic advancements.
